MicroRNAs diagnostic and prognostic value as predictive markers for malignant mesothelioma

References

• Micolucci L, Akhtar MM, Olivieri F, Rippo MR, Procopio AD. Diagnostic value of microRNAs in asbestos exposure and malignant mesothelioma: systematic review and qualitative meta-analysis. Oncotarget. 2016;7(36):58606–58637. doi:10.18632/oncotarget.9686.
   PubMedGoogle Scholar
• Ficociello B, Minoia C, Sturchio E. A key role of microRNAs as early biomarkers in mesothelioma. J Environ Occup Sci. 2013;2(2):89–102. doi:10.5455/jeos.20130809110116.
   Google Scholar
• Tranchant R, Montagne F, Jaurand MC, Jean D. Molecular heterogeneity of malignant pleural mesotheliomas. Bull Cancer. 2018;105(1):35–45. doi:10.1016/j.bulcan.2017.11.007.
   PubMed Web of Science ®Google Scholar
• Sekido Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis. 2013;34(7):1413–1419. doi:10.1093/carcin/bgt166.
   PubMed Web of Science ®Google Scholar
• Toyokuni S. Mechanisms of asbestos-induced carcinogenesis. Nagoya J Med Sci. 2009;71:1–10.
   PubMed Web of Science ®Google Scholar
• Sturchio E, Amadori A, Businaro J, et al. Possible use of microRNAs as biomarkers for monitoring of workers exposed to asbestos. G Ital Med Lav Ergon. 2012;34:571–573.
   PubMedGoogle Scholar
• Christensen BC, Godleski JJ, Marsit CJ, et al. Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma. Carcinogenesis. 2008;29(8):1555–1559. doi:10.1093/carcin/bgn059.
   PubMed Web of Science ®Google Scholar
• Christensen BC, Houseman EA, Godleski JJ, et al. Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome. Cancer Res. 2009;69(1):227–234. doi:10.1158/0008-5472.CAN-08-2586.
   PubMed Web of Science ®Google Scholar
• Goto Y, Shinjo K, Kondo Y, et al. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res. 2009;69(23):9073–9082. doi:0008-5472.CAN-09-1595 doi:10.1158/0008-5472.CAN-09-1595.
   PubMed Web of Science ®Google Scholar
• Fischer JR, Ohnmacht U, Rieger N, et al. Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer. 2006;54(1):109–116. doi:10.1016/j.lungcan.2006.06.017.
   PubMed Web of Science ®Google Scholar
• Batra S, Shi Y, Kuchenbecker KM, et al. Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma. Biochem Biophys Res Commun. 2006;342(4):1228–1232. doi:10.1016/j.bbrc.2006.02.084.
   PubMed Web of Science ®Google Scholar
• Dhalluin X, Scherpereel A. Chemotherapy and radiotherapy for mesothelioma. Recent Results Cancer Res. 2011;189:127–147. doi:10.1007/978-3-642-10862-4_8.
   PubMedGoogle Scholar
• McLoughlin KC, Kaufman AS, Schrump DS. Targeting the epigenome in malignant pleural mesothelioma. Transl Lung Cancer Res. 2017;6(3):350–365. doi:10.21037/tlcr.2017.06.06.
   PubMed Web of Science ®Google Scholar
• Alix-Panabières C, Pantel K. Characterization of single circulating tumor cells. FEBS Lett. 2017;591(15):2241–2250. doi:10.1002/1873-3468.12662.
   PubMed Web of Science ®Google Scholar
• Chen Z, Gaudino G, Pass HI, Carbone M, Yang H. Diagnostic and prognostic biomarkers for malignant mesothelioma: an update. Transl Lung Cancer Res. 2017;6(3):259–269. doi:10.21037/tlcr.2017.05.06.
   PubMed Web of Science ®Google Scholar
• Cui A, Jin XG, Zhai K, Tong ZH, Shi HZ. Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis. BMJ Open. 2014;4(2):e004145. 004145 doi:10.1136/bmjopen-2013-.
   PubMed Web of Science ®Google Scholar
• Carugno M, Consonni D, Bollati V, Pesatori AC. Indicatori molecolari per la diagnosi precoce di mesotelioma in “Claudio Minoia e Pietro Comba. Amianto un Fantasma Del Passato o Una Storia Infinita?Asbestos, a Ghost of the past or a Neverending Story? Vol 2. Cermenate (CO): New Press Edizioni; 2018:980.
   Google Scholar
• Cristaudo A, Bonotti A, Guglielmi G, Fallahi P, Foddis R. Serum mesothelin and other biomarkers: what have we learned in the last decade. J Thorac Dis. 2018;10(S2):S353–S359. doi:10.21037/jtd.2017.10.132.
   PubMedGoogle Scholar
• Johnen G, Burek K, Raiko I, et al. Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin – a case-control comparison nested into a prospective cohort of asbestos-exposed workers. Sci Rep. 2018;8(1):14321. doi:10.1038/s41598-018-32315-3.
   PubMedGoogle Scholar
• Jiménez-Ramírez C, Casjens S, Juárez-Pérez CA, et al. Mesothelin, calretinin, and megakaryocyte potentiating factor as biomarkers of malignant pleural mesothelioma. Lung. 2019;197(5):641–649. doi:10.1007/s00408-019-00244-1.
   PubMed Web of Science ®Google Scholar
• Busacca S, Germano S, De CL, et al. MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am J Respir Cell Mol Biol. 2010;42(3):312–319. doi:10.1165/rcmb.2009-0060OC.
   PubMed Web of Science ®Google Scholar
• Gee GV, Koestler DC, Christensen BC, et al. Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma. Int J Cancer. 2010;127(12):2859–2869. doi:10.1002/ijc.25285.
   PubMed Web of Science ®Google Scholar
• Guled M, Lahti L, Lindholm PM, et al. CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis. Genes Chromosom Cancer. 2009;48(7):615–623. doi:10.1002/gcc.20669.
   PubMed Web of Science ®Google Scholar
• Pass HI, Goparaju C, Ivanov S, et al. Hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer Res. 2010;70(5):1916–1924. doi:10.1158/0008-5472.CAN-09-3993.
   PubMed Web of Science ®Google Scholar
• Kraemer S, Vaught JD, Bock C, et al. From SOMAmer-based biomarker discovery to diagnostic and clinical applications: a SOMAmer-based, streamlined multiplex proteomic assay. PLoS One. 2011;6(10):e26332. doi:10.1371/journal.pone.0026332.
   PubMed Web of Science ®Google Scholar
• Comar M, Zanotta N, Bonotti A, et al. Increased levels of C-C chemokine RANTES in asbestos exposed workers and in malignant mesothelioma patients from an hyperendemic area. PLoS One. 2014;9(8):e104848. doi:10.1371/journal.pone.0104848.
   PubMed Web of Science ®Google Scholar
• Micolucci L, Rippo MR, Olivieri F, Procopio AD. Progress of research on microRNAs with diagnostic value in asbestos exposure: a call for method standardization. BST. 2017;11(1):105–109. doi:10.5582/bst.2016.01249.
   Google Scholar
• Lagniau S, Lamote K, van Meerbeeck JP, Vermaelen KY. Biomarkers for early diagnosis of malignant mesothelioma: do we need another moonshot? Oncotarget. 2017;8(32):53751–53762. doi:10.18632/oncotarget.17910.
   PubMedGoogle Scholar
• O’Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol. 2018;9:402. doi:10.3389/fendo.2018.00402.
   PubMed Web of Science ®Google Scholar
• Griffiths-Jones S, Grocock RJ, van DS, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006;34(90001):D140–D144. doi:10.1093/nar/gkj112.
   PubMedGoogle Scholar
• Reddy KB. MicroRNA (miRNA) in cancer. Cancer Cell Int. 2015;15(1):38. doi:10.1186/s12935-015-0185-1.
   PubMed Web of Science ®Google Scholar
• Lu J, Getz G, Miska EA, Alvarez-Saavedra E, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–838. doi:10.1038/nature03702.
   PubMed Web of Science ®Google Scholar
• Ivanov SV, Goparaju CM, Lopez P, et al. Pro-tumorigenic effects of miR-31 loss in mesothelioma. J Biol Chem. 2010;285(30):22809–22817. doi:10.1074/jbc.M110.100354.
   PubMed Web of Science ®Google Scholar
• Kirschner MB, Cheng YY, Armstrong NJ, Lin R, et al. MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma. Mol Oncol. 2015;9(3):715–726. doi:10.1016/j.molonc.2014.11.007.
   PubMed Web of Science ®Google Scholar
• Birnie KA, Yip YY, Ng DC, et al. Loss of miR-223 and JNK signaling contribute to elevated stathmin in malignant pleural mesothelioma. Mol Cancer Res. 2015;13(7):1106–1118. doi:10.1158/1541-7786.MCR-14-0442.
   PubMed Web of Science ®Google Scholar
• Williams M, Kirschner MB, Cheng YY, Hanh J, et al. miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma. Oncotarget. 2015;6(27):23480–23495. doi:10.18632/oncotarget.4346.
   PubMedGoogle Scholar
• De Santi C, Melaiu O, Bonotti A, et al. Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism. Sci Rep. 2017;7(1):3140. doi:10.1038/s41598-017-02694-0.
   PubMedGoogle Scholar
• Mairinger FD, Werner R, Flom E, et al. miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma. Virchows Arch. 2017;470(6):627–637. doi:10.1007/s00428-017-2133-z.
   PubMed Web of Science ®Google Scholar
• Truini A, Coco S, Nadal E, et al. Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma. Oncotarget. 2017;8(40):68627–68640. doi:10.18632/oncotarget.19800.
   PubMedGoogle Scholar
• Bruno R, Ali G, Fontanini G. Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review. J Thorac Dis. 2018;10(S2):S342–S352. doi:10.21037/jtd.2017.10.88.
   PubMedGoogle Scholar
• He T, McColl K, Sakre N, Chen Y, Wildey G, Dowlati A. Post-transcriptional regulation of PIAS3 expression by miR-18a in malignant mesothelioma. Mol Oncol. 2018;12(12):2124–2135. doi:10.1002/1878-0261.12386.
   PubMed Web of Science ®Google Scholar
• Johnson TG, Schelch K, Cheng YY, et al. Dysregulated expression of the MicroRNA miR-137 and its target YBX1 contribute to the invasive characteristics of malignant pleural mesothelioma. J Thorac Oncol. 2018;13(2):258–272. doi:10.1016/j.jtho.2017.10.016.
   PubMed Web of Science ®Google Scholar
• Nymark P, Guled M, Borze I, et al. Integrative analysis of microRNA, mRNA and aCGH data reveals asbestos- and histology-related changes in lung cancer. Genes Chromosom Cancer. 2011;50(8):585–597. doi:10.1002/gcc.20880.
   PubMed Web of Science ®Google Scholar
• Ledda C, Senia P, Rapisarda V. Biomarkers for early diagnosis and prognosis of malignant pleural mesothelioma: the quest goes on. Cancers. 2018;10(6):203. doi:10.3390/cancers10060203.
   Web of Science ®Google Scholar
• Cheng YY, Wright CM, Kirschner MB, et al. KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma. Mol Cancer. 2016;15(1):44. doi:10.1186/s12943-016-0529-z.
   PubMedGoogle Scholar
• Pardo LA, Stuhmer W. The roles of K(+) channels in cancer. Nat Rev Cancer. 2014;14(1):39–48. doi:10.1038/nrc3635.
   PubMed Web of Science ®Google Scholar
• Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: association with disease and potential use as biomarkers. Crit Rev Oncol Hematol. 2011;80(2):193–208. doi:10.1016/j.critrevonc.2010.11.004.
   PubMed Web of Science ®Google Scholar
• Inamura K. Diagnostic and therapeutic potential of MicroRNAs in lung cancer cancers (Basel). Cancers. 2017;9(12):49. doi:10.3390/cancers9050049.
   Google Scholar
• Pesch B, Bruning T, Johnen G, et al. Biomarker research with prospective study designs for the early detection of cancer. Biochim Biophys Acta. 2014;1844(5):874–883. doi:10.1016/j.bbapap.2013.12.007.
   PubMed Web of Science ®Google Scholar
• Santarelli L, Gaetani S, Monaco F, et al. Four-miRNA signature to identify asbestos-related lung malignancies. Cancer Epidemiol Biomarkers Prev. 2019;28(1):119–126. doi:10.1158/1055-9965.EPI-18-0453.
   PubMed Web of Science ®Google Scholar
• Amati M, Tomasetti M, Scartozzi M, et al. Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study. Cancer Epidemiol Biomarkers Prev. 2008;17(1):163–170. doi:10.1158/1055-9965.EPI-07-0607.
   PubMed Web of Science ®Google Scholar
• Bononi I, Comar M, Puozzo A, et al. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers. Oncotarget. 2016;7(50):82700–82711. doi:10.18632/oncotarget.12408.
   PubMedGoogle Scholar
• Weber DG, Gawrych K, Casjens S, et al. Circulating miR-132-3p as a candidate diagnostic biomarker for malignant mesothelioma. Dis Markers. 2017;2017:1–15. doi:10.1155/2017/9280170.
   Web of Science ®Google Scholar
• Pizzamiglio S, Zanutto S, Ciniselli CM, et al. A methodological procedure for evaluating the impact of hemolysis on circulating microRNAs. Oncol Lett. 2017;13(1):315–320. doi:10.3892/ol.2016.5452777.
   PubMed Web of Science ®Google Scholar
• Tiberio P, Callari M, Angeloni V, Daidone MG, Appierto V. Challenges in using circulating miRNAs as cancer biomarkers. Biomed Res Int. 2015;2015:1–10. doi:10.1155/2015/731479.
   Web of Science ®Google Scholar
• Kirschner MB, Cheng YY, Badrian B, Kao SC, et al. Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. J Thorac Oncol. 2012;7(7):1184–1191. doi:10.1097/JTO.0b013e3182572e83.
   PubMed Web of Science ®Google Scholar
• Weber DG, Johnen G, Bryk O, Jockel KH, Bruning T. Identification of miRNA-103 in the cellular fraction of human peripheral blood as a potential biomarker for malignant mesothelioma–a pilot study. PLoS One. 2012;7(1):e30221. doi:10.1371/journal.pone.0030221.
   PubMed Web of Science ®Google Scholar
• Weber DG, Casjens S, Johnen G, et al. Combination of MiR-103a-3p and mesothelin improves the biomarker performance of malignant mesothelioma diagnosis. PLoS One. 2014;9(12):e114483. doi:10.1371/journal.pone.0114483.
   PubMed Web of Science ®Google Scholar
• Santarelli L, Strafella E, Staffolani S, et al. Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma. PLoS One. 2011;6(4):e18232. doi:10.1371/journal.pone.0018232.
   PubMed Web of Science ®Google Scholar
• Weber DG, Brik A, Casjens S, et al. Are circulating microRNAs suitable for the early detection of malignant mesothelioma? Results from a nested case–control study. BMC Res Notes. 2019;12(1):77. doi:10.1186/s13104-019-4113-7.
   PubMedGoogle Scholar
• Cavalleri T, Angelici L, Favero C, et al. Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease. PLoS One. 2017;12(5):e0176680. doi:10.1371/journal.pone.0176680.
   PubMed Web of Science ®Google Scholar
• Mozzoni P, Ampollini L, Goldoni M, et al. MicroRNA expression in malignant pleural mesothelioma and asbestosis: a pilot study. Dis Markers. 2017;2017:1–10. doi:10.1155/2017/9645940.
   Web of Science ®Google Scholar
• Reid G, Pel ME, Kirschner MB, et al. Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Ann Oncol. 2013;24(12):3128–3135. doi:10.1093/annonc/mdt412.
   PubMed Web of Science ®Google Scholar
• Kao SC, Fulham M, Wong K, et al. A Significant metabolic and radiological response after a novel targeted MicroRNA-based treatment approach in malignant pleural mesothelioma. Am J Respir Crit Care Med. 2015;191(12):1467–1469. doi:10.1164/rccm.201503-0461LE.
   PubMed Web of Science ®Google Scholar
• Gayosso-Gomez LV, Zarraga-Granados G, Paredes-Garcia P, et al. Identification of circulating miRNAs profiles that distinguish malignant pleural mesothelioma from lung adenocarcinoma. EXCLI.J. 2014;13:740–750.
   PubMed Web of Science ®Google Scholar
• Matboli M, Shafei AE, Azazy AE, et al. Clinical evaluation of circulating miR-548a-3p and -20a expression in malignant pleural mesothelioma patients. Biomark Med. 2018;12(2):129–139. doi:10.2217/bmm-2017-0224.
   PubMed Web of Science ®Google Scholar
• Muraoka T, Soh J, Toyooka S, et al. The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma. Lung Cancer. 2013;82(3):485–490. doi:10.1016/j.lungcan.2013.09.017.
   PubMed Web of Science ®Google Scholar
• Jia J, Guo X, Feng L, et al. Genome-wide profiling reveals novel microRNAs in hand-spinning-specific chrysotile exposure. Epigenomics. 2019;11(5):511–525. doi:10.2217/epi-2018-0143.
   PubMed Web of Science ®Google Scholar
• Sestini S, Boeri M, Marchiano A, et al. Lung cancer screening in high-risk subjects: early detection with LDCT and risk stratification using miRNA-based blood test. Epidemiol Prev. 2016;40:42–50. doi:10.19191/EP16.1S1.P042.029.
   PubMed Web of Science ®Google Scholar